| Funding Opportunity ID: |
325615 |
| Opportunity Number: |
RFA-HG-20-016 |
| Opportunity Title: |
Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.350 |
| Eligible Applicants: |
Small businesses |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Mar 19, 2020 |
| Close Date: |
Jun 24, 2022 |
| Last Updated Date: |
Mar 19, 2020 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics. |
| Version: |
1 |
